×
About 75,119 results
FDA approves first generics of Gilenya
https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-gilenya
FDA

Dec 8th, 2019 - The U.S. Food and Drug Administration has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.

Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.040267
Circulation Schnabel RB, et al

Nov 25th, 2019 - Cardiac thromboembolism attributed to atrial fibrillation (AF) is responsible for up to one-third of ischemic strokes. Stroke may be the first manifestation of previously undetected AF. Given the efficacy of oral anticoagulants in preventing AF-related ischemic strokes, strategies of searching for AF after a stroke using ECG monitoring followed by oral anticoagulation (OAC) treatment have been ...

Eastern Equine Encephalitis Virus — Another Emergent Arbovirus in the United States
https://www.nejm.org/doi/full/10.1056/NEJMp1914328
New England Journal of Medicine; David M. Morens, M.D. et. al.

Nov 24th, 2019 - Humans have always lived in intimate association with arthropods that transmit pathogens between humans or from animals to humans. About 700,000 deaths due to vectorborne diseases occur globally each year, according to World Health Organization estimates. In the summer and fall of 2019, nine U.S. states have reported 36 human cases (14 of them fatal) of one of the deadliest of these diseases: e...

The Management of Stroke Rehabilitation: A Synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline
https://annals.org/aim/fullarticle/2755728/management-stroke-rehabilitation-synopsis-2019-u-s-department-veterans-affairs
Annals of Internal Medicine; James Sall, et al

Nov 20th, 2019 - In June 2019, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved an update of the joint clinical practice guideline for rehabilitation after stroke. This synopsis summarizes the key recommendations from this guideline.

Depression in Children and Adolescents: Evaluation and Treatment
https://www.aafp.org/afp/2019/1115/p609.html
American Family Physician; Selph SS et al

Nov 16th, 2019 - he prevalence of major unipolar depression in children and adolescents is increasing in the United States. In 2016, approximately 5% of 12-year-olds and 17% of 17-year-olds reported experiencing a major depressive episode in the previous 12 months. Screening for depression in adolescents 12 years and older should be conducted annually using a validated instrument, such as the Patient Health Que...

Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000740
Circulation Peter A. Noseworthy, et al.

Nov 14th, 2019 - The widespread use of cardiac implantable electronic devices and wearable monitors has led to the detection of subclinical atrial fibrillation in a substantial proportion of patients. There is evidence that these asymptomatic arrhythmias are associated with increased risk of stroke. Thus, detection of subclinical atrial fibrillation may offer an opportunity to reduce stroke risk by initiating a...

Cannabidiol as a potential treatment for psychosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843725/
Therapeutic Advances in Psychopharmacology; Davies C, et al

Nov 7th, 2019 - Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treatment of psychotic disorders and they remain the mainstay of our treatment arsenal for psychosis. However, traditional antipsychotics are associated wi...

BIOGEN AND ALKERMES ANNOUNCE FDA APPROVAL OF VUMERITY™ (DIROXIMEL FUMARATE) FOR MULTIPLE SCLEROSIS
http://investors.biogen.com/news-releases/news-release-details/biogen-and-alkermes-announce-fda-approval-vumeritytm-diroximel

Nov 5th, 2019 - Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease...

Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials
https://jnnp.bmj.com/content/early/2019/08/29/jnnp-2019-320912
Journal of Neurology, Neurosurgery, & Psychiatry; Bai. S., et al

Oct 27th, 2019 - Objectives To systematically review the efficacy and safety of anti-inflammatory agents for patients with major depressive disorders. Methods We searched the literature to identify potentially relevant randomised controlled trials (RCTs) up to 1 January 2019. The primary outcome was efficacy, measured by mean changes in depression score from baseline to endpoint. Secondary outcomes included ...

Asthma in Adults
https://www.sciencedirect.com/science/article/abs/pii/S0025712519300896?via%3Dihub
Medical Clinics of North America; Nanda A, et al

Oct 27th, 2019 - Asthma affects approximately 300 million people worldwide and approximately 7.5% of adults in the United States. Among adults, asthma results in about 10.5 million physician office visits per year and affects approximately 8.7% of blacks, 7.6% of whites, and 5.8% of Hispanics. Asthma is characterized by inflammation of airways, variable airflow obstruction, and bronchial hyperresponsiveness.3 I...

FDA Approves Botox® (Onabotulinumtoxina) For Pediatric Patients With Lower Limb Spasticity, Excluding Spasticity Caused By Cerebral Palsy
https://www.allergan.com/News/Details/2019/10/FDA%20Approves%20BOTOX%20onabotulinumtoxinA%20for%20Pediatric%20Patients%20with%20Lower%20Limb%20Spasticity%20Excluding%20Sp

Oct 23rd, 2019 - Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) for BOTOX® for the treatment of pediatric patients (2 to 17 years of age) with lower limb spasticity, excluding spasticity caused by cerebral palsy (CP). This marks the 11th BOTOX® therapeutic indication, having been approved for pedi...

FDA, FTC warn company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD, Parkinson’s and Alzheimer’s disease
https://www.fda.gov/news-events/press-announcements/fda-ftc-warn-company-marketing-unapproved-cannabidiol-products-unsubstantiated-claims-treat-teething

Oct 21st, 2019 - Today, the U.S. Food and Drug Administration and the Federal Trade Commission posted a joint warning letter to Rooted Apothecary LLC, of Naples, Florida, for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat teething pain and ear aches in infants, autism, attention-deficit/hyperactivity disorder (ADHD), as well as Parki...

2019 Supportive Care: Anxiety, Depression, and Low Social Support Are Significant Factors in Cancer Pain Intensity
https://ascopost.com/news/october-2019/anxiety-depression-and-low-social-support-are-significant-factors-in-cancer-pain-intensity/

Oct 21st, 2019 - Pain is one of the most common symptoms associated with cancer and its treatment, and feelings of anxiety and depression can intensify the level of pain patients experience, according to the results from a study by Galloway et al that will be presented at the 2019 Supportive Care in Oncology Symposium (Abstract 76). However, authors also reported that having greater social support can help miti...

U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
http://www.noven.com/PR101519.php

Oct 14th, 2019 - Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration (FDA) has approved SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch formulation for the treatment of adults with schizophrenia.1 “As people living with schizophrenia cycle through treatments their therapeutic options ...

FDA approves new treatment for patients with migraine
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine

Oct 10th, 2019 - The U.S. Food and Drug Administration today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated for the preventive treatment of migraine.

Coverage from the International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2019
https://www.medscape.com/viewcollection/35073

Oct 8th, 2019 - International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2019: Read clinically focused news coverage of key developments from MDS 2019

Cannabis and cannabinoids for people with multiple sclerosis
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013444/full

Oct 6th, 2019 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess benefit and safety of cannabis‐based medicines, including synthetic, or herbal and plant‐derived cannabinoids, for people with MS.

Sleeping less than six hours and heart disease, stroke – deadly combo
https://newsroom.heart.org/news/sleeping-less-than-six-hours-and-heart-disease-stroke-deadly-combo

Oct 1st, 2019 - Middle-aged adults with high blood pressure, Type 2 diabetes, heart disease or stroke could be at increased risk for cancer and early death when sleeping less than 6 hours per day.

Anticoagulation: Updated Guidelines for Outpatient Management
https://www.aafp.org/afp/2019/1001/p426.html
American Family Physician;

Sep 30th, 2019 - Anticoagulation therapy is recommended for preventing, treating, and reducing the recurrence of venous thromboembolism, and preventing stroke in persons with atrial fibrillation. Direct oral anticoagulants are first-line agents for eligible patients for treating venous thromboembolism and preventing stroke in those with nonvalvular atrial fibrillation. Vitamin K antagonists are recommended for ...

Protein Oxidation Biomarkers & Myeloperoxidase Activation in Cerebrospinal Fluid in Childhood Bacterial Meningitis
https://www.ncbi.nlm.nih.gov/pubmed/31581487
Antioxidants (Basel); Rugemalira E, et al

Sep 30th, 2019 - The immunological response in bacterial meningitis (BM) causes the formation of reactive oxygen and nitrogen species (ROS, RNS) and activates myeloperoxidase (MPO), an inflammatory enzyme. Thus, structural oxidative and nitrosative damage to proteins and DNA occurs. We aimed to asses these events in the cerebrospinal fluid (CSF) of pediatric BM patients.

Medical education needs to stop burning out students — now
https://www.statnews.com/2019/08/29/medical-education-stop-burning-out-students/

Sep 28th, 2019 - Students’ time in medical school should help them grow and become insightful, caring doctors. Instead, medical education is somehow turning smart, gifted, enthusiastic applicants into exhausted and unhappy students who become interns, residents, and physicians at increased risk of depression and burnout.

Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease
https://www.nejm.org/doi/full/10.1056/NEJMoa1909406

Sep 27th, 2019 - BACKGROUND Long-term outcomes after percutaneous coronary intervention (PCI) with contemporary drug-eluting stents, as compared with coronary-artery bypass grafting (CABG), in patients with left main coronary artery disease are not clearly established. METHODS We randomly assigned 1905 patients with left main coronary artery disease of low or intermediate anatomical complexity (according t...

International Congress of Parkinson’s Disease and Movement Disorders Final Program
https://www.mdscongress.org/Congress-Branded/19FP-_blue_puzzle_online.pdf

Sep 25th, 2019 - On behalf of the International Parkinson and Movement Disorder Society (MDS), we are pleased to welcome you to the International Congress of Parkinson’s Disease and Movement Disorders. Nice is a charming, picturesque city nestled on the southeast coast of France at the foot of the Alps and extending along the Mediterranean Sea. In addition to the draw of the dynamic landscape, including the ...

Pesticide exposure may increase heart disease and stroke risk
https://newsroom.heart.org/news/pesticide-exposure-may-increase-heart-disease-and-stroke-risk

Sep 24th, 2019 - On-the-job exposure to high levels of pesticides raised the risk of heart disease and stroke in a generally healthy group of Japanese American men in Hawaii, according to new research published in the Journal of the American Heart Association, the open access journal of the American Heart Association.

Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study
http://www.cmaj.ca/content/191/37/E1018
CMAJ

Sep 15th, 2019 - BACKGROUND: Donepezil, rivastigmine and galantamine are popular cholinesterase inhibitors used to manage the symptoms of Alzheimer disease and other dementias; regulatory agencies in several countries warn about a possible risk of rhabdomyolysis with donepezil, based on information from case reports. Our goal was to investigate the 30-day risk of admission to hospital with rhabdomyolysis associ...

Interventions to Prevent Perinatal Depression: Recommendation Statement
https://www.aafp.org/afp/2019/0915/od1.html
American Family Physician;

Sep 14th, 2019 - The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions

Advanced MRI brain scan may help predict stroke-related dementia
https://newsroom.heart.org/news/advanced-mri-brain-scan-may-help-predict-stroke-related-dementia

Sep 11th, 2019 - An advanced Magnetic Resonance Imaging (MRI) brain scan analysis in patients with stroke-related, small vessel disease helped predict problems with thinking, memory and even dementia, according to new research published in Stroke, a journal of the American Stroke Association, a division of the American Heart Association.

Associations of Subjective Memory Complaints and Simple Memory Task Scores With Future Dementia in the Primary Care Setting
http://www.annfammed.org/content/17/5/412.full
Annals of Family Medicine;

Sep 9th, 2019 - PURPOSE Family physicians need simple yet comprehensive algorithms to discriminate between community-dwelling older persons who are at increased risk of dementia and those who are not. We aimed to investigate associations between incident dementia and responses to a single question regarding subjective memory complaints (SMC) combined with scores on 2 simple memory tests that are easy to use in...

Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial
https://annals.org/aim/article-abstract/2749725/menopausal-estrogen-alone-therapy-health-outcomes-women-without-bilateral-oophorectomy
Annals of Internal Medicine;

Sep 9th, 2019 - Background: Whether health outcomes of menopausal estrogen therapy differ between women with and without bilateral salpingo-oophorectomy (BSO) is unknown. Objective: To examine estrogen therapy outcomes by BSO status, with additional stratification by 10-year age groups. Design: Subgroup analyses of the randomized Women's Health Initiative Estrogen-Alone Trial. (ClinicalTrials.gov: NCT...

Antiviral treatment for Bell's palsy (idiopathic facial paralysis)
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001869.pub9/full
Cochrane Database of Systematic Reviews;

Sep 4th, 2019 - Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. This review was first published in 2001 and most recently updated in 2015. Since a significant benefit of corticosteroids for the early management of Bell's palsy has been demonstrated, the main focus of this update, ...

Trial of SAGE-217 in Patients with Major Depressive Disorder
https://www.nejm.org/doi/full/10.1056/NEJMoa1815981
The New England Journal of Medicine; Gunduz-Bruce, H. et. al.

Sep 4th, 2019 - Altered neurotransmission of γ-aminobutyric acid (GABA) has been implicated in the pathogenesis of depression. Whether SAGE-217, an oral, positive allosteric modulator of GABA type A receptors, is effective and safe for the treatment of major depressive disorder is unknown.

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
https://www.nejm.org/doi/full/10.1056/NEJMoa1908973?query=featured_home
The New England Journal of Medicine; Schüpke, S. et. al.

Aug 31st, 2019 - BACKGROUND The relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain. METHODS In this multicenter, randomized, open-label trial, we randomly assigned patients who presented with acute coronary syndromes and for whom invasive evaluation was planned to receive either ticagrelor or prasugrel. Th...

Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population
https://www.nature.com/articles/s41591-019-0547-7
Nature Medicine; Licher, S. et. al.

Aug 25th, 2019 - The exact etiology of dementia is still unclear, but both genetic and lifestyle factors are thought to be key drivers of this complex disease. The recognition of familial patterns of dementia has led to the discovery of genetic factors that have a role in the pathogenesis of dementia, including the apolipoprotein E (APOE) genotype and a large and still-growing number of genetic variants1,2. Bey...

Unraveling the Safety Profile of Proton-Pump Inhibitors
https://www.jwatch.org/na49660/2019/08/19/unraveling-safety-profile-proton-pump-inhibitors
Journal Watch;

Aug 19th, 2019 - Proton-pump inhibitors (PPIs) provide important clinical benefits for many patients. However, observational studies have suggested an association between PPI use and a variety of adverse events, including dementia, osteoporosis, bone fractures, micronutrient deficiencies, pneumonia, spontaneous bacterial peritonitis, kidney disease, and enteric infections. We have observed that some patients wi...

Insomnia tied to higher risk of heart disease and stroke
https://newsroom.heart.org/news/insomnia-tied-to-higher-risk-of-heart-disease-and-stroke

Aug 18th, 2019 - People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke, according to new research in the American Heart Association’s journal Circulation. Previous observational studies have found an association between insomnia, which affects up to 30% of the general population, and an increased risk of developing heart disease and stroke. These obse...

Intensive blood pressure management may preserve brain health
https://www.mdlinx.com/neurology/top-medical-news/article/2019/08/14/7575730

Aug 13th, 2019 - Numerous large, cohort studies have linked midlife hypertension to mild cognitive impairment and dementia later on. Some of these studies found a higher risk of lesions in the brain's white matter in older age among people with high blood pressure in their 50s. The white matter of the brain consists of bundles of axons, which are the thin elongations of neurons. White matter is "white" due to m...

FDA warns consumers about the dangerous and potentially life threating side effects of Miracle Mineral Solution
https://www.fda.gov/news-events/press-announcements/fda-warns-consumers-about-dangerous-and-potentially-life-threating-side-effects-miracle-mineral

Aug 11th, 2019 - The U.S. Food and Drug Administration is warning consumers not to purchase or drink a product sold online as a medical treatment due to a recent rise in reported health issues. Since 2010, the FDA has warnedExternal Link Disclaimer consumers about the dangers of Miracle or Master Mineral Solution, Miracle Mineral Supplement, MMS, Chlorine Dioxide (CD) Protocol, Water Purification Solution (WPS)...

An alternate theory for what causes Alzheimer's disease
https://medicalxpress.com/news/2019-08-alternate-theory-alzheimer-disease.html

Aug 11th, 2019 - Alzheimer's disease, the most common cause of dementia among the elderly, is characterized by plaques and tangles in the brain, with most efforts at finding a cure focused on these abnormal structures. But a University of California, Riverside, research team has identified alternate chemistry that could account for the various pathologies associated with the disease.

Spinal muscular atrophy - Genetics Home Reference - NIH
https://ghr.nlm.nih.gov/condition/spinal-muscular-atrophy

Aug 5th, 2019 - Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body's center ...

Cochrane for Clinicians: Vaccines for Preventing Influenza in Healthy Children, Healthy Adults, and Older Adults
https://www.aafp.org/afp/2019/0801/p143.html
American Family Physician;

Jul 31st, 2019 - Clinical Question Do influenza vaccines reduce the risk of influenza in healthy children, healthy adults, and older adults? Evidence-Based Answer Influenza vaccination reduces rates of laboratory-confirmed influenza and symptomatic influenza-like illness in healthy children, healthy adults, and older adults. There is no consistent evidence that influenza vaccination reduces school absentee...

Clinical Practice Guideline: Sudden Hearing Loss (Update)
https://journals.sagepub.com/doi/pdf/10.1177/0194599819859885
Chandrasekhar, S. et. al.

Jul 31st, 2019 - Sudden hearing loss is a frightening symptom that often prompts an urgent or emergent visit to a health care provider. It is frequently but not universally accompanied by tinnitus and/or vertigo. Sudden sensorineural hearing loss affects 5 to 27 per 100,000 people annually, with about 66,000 new cases per year in the United States. This guideline update provides evidence-based recommendations f...

Association of Hearing Loss With Dementia
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2740068
Liu. C., et al

Jul 30th, 2019 - Question What is the association of hearing loss with future incident dementia in the general population of Taiwan? Findings In this population-based matched cohort study of 16 270 participants, hearing loss was positively associated with incident dementia, especially in patients aged 45 to 64 years. Meaning Hearing loss is associated with a higher risk of dementia, and findings sugges...

The Family Physician’s Role in the Prevention of Measles
https://www.aafp.org/dam/AAFP/documents/journals/afp/MeaslesEditorial.pdf
American Family Physician;

Jul 28th, 2019 - Measles is one of the most highly transmissible diseases, with 90% of unvaccinated persons infected after contact.1 In 2000, the Centers for Disease Control and Prevention (CDC) declared that measles was eliminated in the United States, but that elimination status may be revoked if the current chain of measles transmission and outbreaks continues for one year, through the fall of 2019. As ...

Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke
https://jamanetwork.com/journals/jama/article-abstract/2738553
JAMA

Jul 22nd, 2019 - Question Does intensive glucose control improve functional outcome in patients with hyperglycemic acute ischemic stroke? Findings This randomized clinical trial included 1151 adults who received either intensive treatment of hyperglycemia (target blood glucose concentration of 80-130 mg/dL) or standard treatment of hyperglycemia (target glucose concentration of 80-179 mg/dL). The proportio...

FDA approves first generics of Lyrica
https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-lyrica

Jul 21st, 2019 - On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, for the management of fibromyalgi...

WHO recommends dolutegravir as preferred HIV treatment option in all populations
https://www.who.int/news-room/detail/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations

Jul 21st, 2019 - Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential. Initial studies had highlighted a possible link between DTG and neural tube defects (birth defects of the brain and spinal cord that cause co...

Randomized Controlled Phase 2a Study of RPh201 in Previous Nonarteritic Anterior Ischemic Optic Neuropathy
https://journals.lww.com/jneuro-ophthalmology/Abstract/publishahead/Randomized_Controlled_Phase_2a_Study_of_RPh201_in.99147.aspx
Rath, E. et. al.

Jul 21st, 2019 - Background: No proven treatment exists for nonarteritic anterior ischemic optic neuropathy (NAION), either in the acute or late phase. Objective: To assess safety and changes in visual function and structure after RPh201/placebo treatment in participants with previous NAION. Design and Setting: Phase 2a, single-site, prospective, randomized, placebo-controlled, double-masked trial (regist...

Intensive Lipid Lowering in Elderly Patients
https://jamanetwork.com/journals/jamacardiology/article-abstract/2738100
JAMA Cardiology; Gotto, A.

Jul 16th, 2019 - In this issue of JAMA Cardiology, a prespecified post hoc analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) examines the effect of age on higher-intensity lipid lowering in patients after an acute coronary syndrome.1 The IMPROVE-IT study was a large, randomized, double-blind clinical trial of individuals with recent acute coronary syndrome.2 Inves...

Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography
https://jamanetwork.com/journals/jamaneurology/fullarticle/2738356
JAMA Neurology; Mattsson, N. et. al.

Jul 16th, 2019 - Question Can a longitudinally valid in vivo β-amyloid staging system be constructed for Alzheimer disease? Findings In this multicenter longitudinal cohort study, a 4-level staging system using fluorine 18–labeled florbetapir positron emission tomography was defined using a combination of cerebrospinal fluid and positron emission tomography data. The β-amyloid stages had distinct associati...

Risk of Acute Myocardial Infarction and Ischemic Stroke in Patients with Asthma Exacerbation: A Population-Based, Self-Controlled Case Series Study
https://www.sciencedirect.com/science/article/abs/pii/S2213219819306178?via%3Dihub
The Journal of Allergy and Clinical Immunology: In Practice; Raita, Y. et. al.

Jul 15th, 2019 - Background Patients with asthma have a high incidence of acute myocardial infarction and ischemic stroke. Objective To investigate the acute effect of asthma exacerbation on these cardiovascular events. Methods Using population-based inpatient data of 3 geographically diverse US states (Florida, Nebraska, and New York) during the period 2011 to 2014, we conducted a self-controlled case...